Ozempic is the brand name for semaglutide marketed by Novo Nordisk. Behind the brand sits one of the most extensively researched peptides of the past decade — a long-acting GLP-1 receptor agonist that has redefined obesity research. This article unpacks the mechanism, the published trial data, and what the research literature actually shows.
What semaglutide is at the molecular level
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1) — a 30 amino-acid incretin hormone the gut releases after meals. The synthetic peptide modifies the native sequence at two residues (Aib at position 8, Arg at position 34) and attaches a fatty-acid sidechain via a glutamate linker. The fatty acid binds reversibly to serum albumin, extending plasma half-life from minutes to roughly 7 days.
How GLP-1 receptor activation drives weight loss
Once semaglutide binds the GLP-1 receptor, the downstream effects converge on three systems:
- Central appetite suppression — GLP-1 receptors in the hypothalamus and brainstem reduce hunger signalling and increase satiety
- Delayed gastric emptying — food remains in the stomach longer, prolonging fullness
- Glucose-dependent insulin secretion — improves glycaemic control without hypoglycaemia risk in research models
The combination produces a sustained reduction in caloric intake. Energy expenditure changes are minor compared with appetite suppression — semaglutide acts on the intake side of the energy balance equation.
STEP trial data — the published endpoints
The STEP (Semaglutide Treatment Effect in People with obesity) programme covers multiple phase 3 trials. The headline result from STEP 1 (Wilding et al., NEJM 2021) reports approximately 14.9% body weight reduction at 68 weeks with weekly 2.4 mg semaglutide in adults with obesity — versus 2.4% with placebo. STEP 3, 4, 5 trials show consistent results across diet-only, weight maintenance, and longer-duration cohorts.
Why the brand naming matters
The same molecule is sold under different brands depending on the regulated indication:
- Ozempic — 0.25–2.0 mg weekly, type 2 diabetes indication
- Wegovy — 2.4 mg weekly, chronic weight management indication
- Rybelsus — oral tablet form for type 2 diabetes
Same molecule. Different formulations and approved indications. See our brand comparison for the full breakdown.
Side effects in the research record
The most-reported adverse events in STEP trials are gastrointestinal — nausea (44% in STEP 1), diarrhoea, constipation, and vomiting. Most are mild to moderate and decline with continued exposure. Serious events are rare but include pancreatitis, gallbladder complications, and (in animal models) C-cell hyperplasia. These data come from published clinical research, not promotional material.
What the data does not show
Weight loss outcomes vary considerably across individuals. Approximately one-third of STEP 1 participants achieved ≥20% weight loss; another third lost less than 10%. Genetic, behavioural, and dose-titration factors explain part of the variance. Long-term durability beyond 2 years remains under study.
Research handling notes
Semaglutide is supplied lyophilised for research applications. Reconstitution in bacteriostatic water at 5–10 mg/mL is typical for stability protocols. See our solvent comparison guide for protocol detail.
Chempeptides supplies HPLC-verified semaglutide with batch-specific CoA — see the research catalogue for current availability.
Research use only. The literature summarised above is from published clinical research. This article is not medical advice.